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Abstract 24 
The present study examined the effect of intensive training in combination with marked reduction in 25 
training volume on FXYD1 expression and phosphorylation at rest and during exercise. Eight well-26 
trained cyclist replaced their regular training with speed-endurance training (10-12 x ~30-s sprints) 27 
2-3 times per week and aerobic high-intensity training (4-5 x 3-4 min at 90-95% of peak aerobic 28 
power output) 1-2 times per week for seven weeks and reduced the training volume by 70%. 29 
Muscle biopsies were obtained before and during a repeated high-intensity exercise protocol and 30 
protein expression and phosphorylation were determined by western blotting. Expression of 31 
FXYD1 (30%), actin (40%), mTOR (12%), PLN (16%) and CaMKII γ/δ (25%) was higher 32 
(P<0.05) after compared to before the training intervention. In addition, after the intervention non-33 
specific FXYD1 phosphorylation was higher (P<0.05) at rest and during exercise, mainly achieved 34 
by an increased FXYD1 ser68 phosphorylation, compared to before the intervention. CaMKII 35 
thr287 and eEF2 thr56 phosphorylation at rest and during exercise, overall PKCα/β thr638/641 and 36 
mTOR ser2448 phosphorylation during repeated intense exercise as well as resting PLN thr17 37 
phosphorylation were also higher (P<0.05) after compared to before the intervention period. Thus, a 38 
period of high intensity training with reduced training volume increases expression and 39 
phosphorylation levels of FXYD1, which may affect Na+/K+ pump activity and muscle K+ 40 
homeostasis during intense exercise. Furthermore, higher expression of CaMKII and PLN as well as 41 
increased phosphorylation of CaMKII thr287 may have improved intracellular Ca2+ handling. 42 
 43 
Abbreviations 44 
4E-BP1, eukaryotic initiation factor 4E-binding protein 1; ACC, Acetyl-CoA carboxylase; AMPK, 45 
AMP-activated Protein Kinase; CaMK, Ca2+/Calmodulin-dependent Protein Kinase; eEF2, 46 
eukaryotic elongation factor 2; FXYD1, phospholemman; mTOR, mammalian target of rapamycin; 47 
NaK, Na+/K+; p70S6K1, Ribosomal protein S6 p70 Kinase 1; PKC, protein kinase C; PLN, 48 
phospholamban; TBST, Tris-buffered Saline including 0.1% Tween-20.  49 
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Introduction 50 
Changes in muscle ion homeostasis during intense contraction reduce membrane excitability which 51 
may lead to development of fatigue (30). Exercise training improves performance during intense 52 
exercise and reduces the accumulation of potassium in both blood (25) and muscle interstitium (32), 53 
which has been associated with elevated levels of Na+/K+ (NaK) pump subunit expression (25; 31-54 
33). However, training studies have shown improved work capacity without adaptations in the NaK 55 
pump content and isoform abundance but with a higher maximal NaK pump activity (3). Thus, 56 
factors other than NaK pump subunits expression may affect the capacity of the NaK pump. 57 
Phospholemman (FYXD1) is a regulatory protein associated with the NaK pump and changes in its 58 
expression and phosphorylation affect pump activity (7; 13; 27; 35). It is well known that muscle 59 
NaK pump activity increases markedly with exercise (9), which may be regulated partly by an 60 
increased FXYD1 phosphorylation observed during both moderate intensity (5) and high intensity 61 
acute exercise in humans (52). The effect of endurance training on muscle FXYD1 expression and 62 
phosphorylation during and after exercise has been examined (5). Ten days of moderate intensity 63 
cycle training including 6 x 5 min at 90-100% of an intensity corresponding to VO2 max did not 64 
affect FXYD1 expression or FXYD1 phosphorylation during long-term low intensity exercise in 65 
untrained healthy individuals (5). In contrast, a 2-week period of high intensity exercise training 66 
elevated resting levels of FXYD1 phosphorylation (54), indicating that intensity during training 67 
may be important for the adaptations of FXYD1. However, the effect of intense training on muscle 68 
FXYD1 expression and exercise-induced phosphorylation has not been examined. We hypothesize 69 
that intensified training does lead to higher expression of FXYD1 and increased FXYD1 70 
phosphorylation during intense exercise, which can explain the  finding of a lower femoral venous 71 
potassium concentration after intense exercise (23).   72 
Exercise training leads to multiple adaptations in human skeletal muscles as a result of molecular 73 
events, including exercise-induced activation of signaling pathways, which regulate changes of 74 
muscle structure and function. AMP-activated Protein Kinase (AMPK) is known as a key protein 75 
for exercise-mediated muscle adaptations and particular regulation of mitochondrial and GLUT4 76 
biogenesis (44). AMPK content, activity and phosphorylation are markedly regulated during a few 77 
weeks of endurance training (17; 29). On the other hand, AMPK thr172 phosphorylation is elevated 78 
after high, but not low, intensity exercise (15). Furthermore, AMPK and Acetyl-CoA carboxylase 79 
(ACC) phosphorylation are increased after four 30-s bouts of intense exercise (21), indicating that 80 
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high intensity exercise training, including training intensities exceeding VO2 max, may lead to 81 
adaptations in the AMPK signaling pathway, but this issue has not been investigated. 82 
Regulation of muscle Ca2+ fluxes during exercise does affect the development of fatigue (1). In 83 
human skeletal muscles the multifunctional Ca2+/Calmodulin-dependent protein kinase (CaMK) II 84 
is the major CaMK and was shown to be activated during low intensity exercise (48). Furthermore, 85 
endurance training alters CaMKII cell signaling in human skeletal muscles (47). In contrast, 86 
CaMKII thr287 phosphorylation is only elevated after high, and not low, intensity exercise (15). 87 
Therefore, high intensity exercise training may induce adaptations in the CaMKII pathway via 88 
changes in CaMKII thr287 phosphorylation, which will affect phospholamban (PLN) thr17 89 
phosphorylation and thereby Ca2+ fluxes via the SERCA pumps (48). 90 
Mammalian target of rapamycin (mTOR) is part of the multi-protein complex, mTORC1, and plays 91 
via e.g. eukaryotic initiation factor 4E-binding protein (4E-BP1) and ribosomal protein S6 p70 92 
kinase 1 (p70S6K1) an essential role in the regulation of muscle mass and protein synthesis (22). 93 
Phosphorylation of mTOR ser2448 and activation of mTORC1 have been associated with both 94 
atrophy and hypertrophy of skeletal muscles (22; 42). Endurance exercise induces an increased 95 
mTOR signaling via phosphorylation of mTOR ser2448 (4) and heavy resistance exercise induces 96 
increases in mTOR signaling and protein synthesis (22). On the other hand, four 30-s sprints did not 97 
activate mTOR signaling (21), while other studies implementing high intensity exercise do report 98 
activation of mTOR signaling (22). Due to the ambiguous findings it is of value to examine whether 99 
intense exercise induces mTOR signaling and how intensified training affects mTOR signaling. 100 
Thus, the aim of the present study was to examine the effects of intense training with reduced 101 
volume on FXYD1 expression and phosphorylation during repeated high intensity exercise in 102 
trained individuals. In addition, to examine the effect of intensified training with a reduced volume 103 
on activation of signaling pathways involving mTOR, AMPK and CaMKII in human skeletal 104 
muscles. 105 
  106 
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Materials and Methods 107 
Ethical approval and subjects 108 
The study was approved by the local ethical committee of the capital region of Copenhagen (Region 109 
Hovedstaden) and performed in accordance to the principles of the Declaration of Helsinki. The 110 
subjects and training intervention were the same as in a study focusing on adaptations of ion 111 
transport proteins and ion kinetics (23) and a study focusing on adaptations in oxygen kinetics (8) 112 
during repeated high intensity exercise. Eight well trained male cyclists, who had been training and 113 
competing on a regular basis for at least 3 years, with an average (mean ± SD) age, weight and 114 
maximum oxygen uptake of 33±8 years, 81±8 kg and 59±4 ml·min-1·kg-1, respectively, participated 115 
in the study. The subjects were informed of any risks and discomforts associated with the 116 
experiments before giving their written, informed consent to participate. 117 
 118 
Training intervention 119 
A 7-week intensive training intervention including a volume-reduction was performed, as a one-120 
group longitudinal design immediately after the regular cycling season as described in detail 121 
previously (8; 23). All training sessions were supervised and performed on public roads and on the 122 
subjects’ own bikes. Briefly, the subjects replaced all their regular training with 2-3 sessions of 123 
speed-endurance training a week performed as 10-12 x ~30-s maximal uphill (~6% gradient) cycle 124 
sprinting interspersed by 4.5 min of low intensity exercise and 1-2 sessions a week of aerobic high-125 
intensity training consisting of 4-5 x ~4 min of cycling (2 km flat course) at 90-95% of maximal 126 
heart rate interspersed by 2 min of rest with a work-to-rest ratio of ~2:1. During the training 127 
intervention subjects reduced the training volume by ~70% (62 vs. 211 km/week). 128 
 129 
Experimental design 130 
Subjects carried out two experimental days as well as two performance testing days before and after 131 
the 7-week training intervention as described in detail previously (8; 23). Briefly, on the first 132 
experimental day subjects arrived at the laboratory in the morning at least 60 min after consumption 133 
of a standardized breakfast. After 30 min of supine rest, catheters were inserted into the femoral 134 
artery and vein under local anesthesia, using the Seldinger technique. The catheters were used to 135 
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measure blood flow and for blood sampling. After 30 min of rest subjects cycled for 6 min at 50% 136 
of peak power output on an ergometer bike (Monark, Ergomedic 839E, Vansbro, Sweden), then 137 
after 30 min of rest, for 6 min at 70% of peak power output and 60 min later for 6 min at 70% of 138 
peak power output. Then, after another 60 min of rest, subjects performed a repeated intense 139 
exercise protocol, consisting of 2 min at low intensity (20 W), then intense exercise for 2 min 140 
(EX1), followed by 2.5 min of recovery and 2 min of low intensity exercise (20 W), and then 141 
another intense exercise bout performed to exhaustion (EX2). The intensity during the intense 142 
exercise was 90% of peak aerobic power output (356±6 W). This article focuses on training 143 
adaptations and changes in relation to the repeated intense exercise protocol performed at the end of 144 
one of the two experimental days (Fig.1). 145 
Before the repeated intense exercise protocol, a muscle biopsy (n=7 as one subject did not have 146 
biopsies taken) was obtained from the m. vastus lateralis (6) under local anesthesia (1 ml of 147 
lidocaine, 20 mg/ml without epinephrine) and incisions were made as preparation for the following 148 
three biopsies. A biopsy was collected immediately after EX1, just prior to the low intensity 149 
exercise before EX2 and at exhaustion in EX2 within 10 seconds of exercise cessation with the 150 
subjects still placed on the bike (Fig. 1). All muscle samples were immediately frozen in liquid N2 151 
and stored at -80°C until analyses were initiated. 152 
 153 
Protein expression in muscle homogenate lysates 154 
Protein expression was determined as described previously (54). In short, samples of approximately 155 
2.5 mg freeze dried human muscle tissue were dissected free from blood, fat and connective tissue. 156 
Samples were homogenized for 1 min at 28,5 Hz (Qiagen Tissuelyser II, Retsch GmbH, Haan, 157 
Germany) in a fresh batch of ice-cold buffer containing (in mM): 10% glycerol, 20 Na-158 
pyrophosphate, 150 NaCl, 50 HEPES (pH 7.5), 1% NP-40, 20 β-glycerophosphate, 2 Na3VO4, 10 159 
NaF, 2 PMSF, 1 EDTA (pH 8), 1 EGTA (pH 8), 10 µg/ml Aprotinin, 10 µg/ml Leupeptin and 3 160 
Benzamidine, afterwards rotating for 1 hour at 4 °C and centrifuged at 18,320 G for 20 min at 4 °C 161 
to exclude non dissolved structures. The supernatant (lysate) was collected and used for further 162 
analysis. Total protein concentration in each sample was determined by a BSA standard kit 163 
(Thermo Scientific, USA) and samples were mixed with 6 x Laemmli buffer (7 ml 0.5 M Tris-base, 164 
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3 ml glycerol, 0.93 g DTT, 1 g SDS and 1.2 mg bromophenol blue) and ddH2O to reach equal 165 
protein concentration before protein expression were determined by western blotting. 166 
 167 
Western blotting 168 
Equal amount of total protein were loaded in each well of pre-cast gels (Bio-Rad Laboratories, 169 
USA). All samples from each subject were loaded on the same gel. Proteins were separated 170 
according to their molecular weight by SDS page gel electrophoresis and semi-dry transferred to a 171 
PVDF membrane (BioRad, Denmark). The membranes were blocked in either 2% skimmed milk or 172 
3% BSA in Tris-buffered Saline including 0.1% Tween-20 (TBST) before an overnight incubation 173 
in primary antibody at 4 °C and a subsequent 1 hour incubation in horseradish-peroxidase 174 
conjugated secondary antibody at room temperature. The bands were visualized with ECL 175 
(Millipore) and recorded with a digital camera (ChemiDoc MP Imaging System, Bio-Rad 176 
Laboratories, USA). Densitometry quantification of the western blot band intensity was done using 177 
Image Lab version 4.0 (Bio-Rad Laboratories, USA) and determined as the total band intensity 178 
adjusted for background intensity. Representative blots are shown in Figure 2. 179 
 180 
Antibodies 181 
The primary antibodies used in the present experiment were optimized by use of mixed human 182 
muscle standard lysates to ensure that the protein amount loaded would result in band signal 183 
intensities localized on the steep and linear part of a standard curve. To determine total and 184 
phospho-specific protein expression the antibodies included in Table 1 were used with the 185 
localization of the quantified signal noted. The phospho-specific Acetyl-CoA carboxylase (ACC) α 186 
ser79 antibody (#07-303, Millipore) was previously shown to recognize the equivalent ser221 in 187 
human ACC β (45; 57) and therefore used to determine ACC β ser221 phosphorylation. The 188 
secondary antibodies used were horseradish-peroxidase conjugated rabbit anti-sheep (P-0163), 189 
rabbit anti-goat (P-0449), goat anti-mouse (P-0447, DAKO, Denmark) and goat anti-rabbit IgM/IgG 190 
(4010-05 Southern Biotech). 191 
 192 
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FXYD1 antibody phospho-specificity 193 
All of the FXYD1 antibodies used in the present study were previously shown to detect FXYD1 in 194 
human skeletal muscle (5; 52) as well as FXYD1 in other tissues (18; 41; 50). In order to interpret 195 
the data meaningfully, it should be noted, that AB_FXYD1 recognizes mainly unphosphorylated 196 
FXYD1, however, phosphorylation at ser63, ser68 and thr69 reduces the AB_FXYD1 signal 197 
intensity, as the antibody epitope is located in the C-terminal region of FXYD1 protein, where the 198 
phosphorylation sites are also located (5; 41; 50; 53). This was confirmed in the present study by 199 
dephosphorylation of the membrane proteins (43) after the original western blot analysis with 200 
AB_FXYD1: The original PVDF membrane was first reactivated in ethanol and afterwards 201 
incubated in TBST. Then the membrane was incubated in a stripping buffer (0.5 M Tris-HCL; pH 202 
6.7, 2% SDS and 100 mM 2-Mercaptoethanol) at 50 °C for 2 hours. After 3 x 10 min washing in 203 
TBST in another container, the membrane was blocked with TBST including 2% skimmed milk in 204 
15 min and incubated in secondary antibody for 1 hour. Membranes were then washed again for 3 x 205 
15 min and the stripping procedure was confirmed by exposure of the membrane. When the entire 206 
primary antibody was removed by the stripping protocol, the dephosphorylation protocol was 207 
conducted by incubating membranes for 2 hours at 37 °C in the dephosphorylation buffer (50 mM 208 
Tris-HCL, 0.1 mM Na2EDTA, 5 mM DTT, 0.01% Brij 35 and 2 mM MnCl2; pH 7.5) including 500 209 
U/ml lambda protein phosphatase (P07535, New England BioLabs). Then the membrane was 210 
blocked with TBST including 2% skimmed milk, incubated overnight in AB_FXYD1, washed 2 x 5 211 
min in TBST, incubated for 1 hour in secondary antibody and exposed by ECL. Following this 212 
procedure, total FXYD1 expression (using AB_FXYD1 on dephosphorylated proteins) was shown 213 
to be significantly increased (0.91±0.05 vs. 1.04±0.06) after compared to before the training 214 
intervention. A similar result (30% increase) was obtained with the total FXYD1 antibody (Table 215 
2), raised against the N-terminal region of the FXYD1, confirming the AB_FXYD1 phospho-216 
specificity. For clarity purposes, data obtained with AB_FXYD1 is inverted and shown as 217 
1/AB_FXYD1, thus an increase on the figure (Fig. 3A) represents an increase in non-specific 218 
FXYD1 phosphorylation. 219 
AB_FXYD1ser68 (originally named CP68) is phospho-specific for ser68 residue in humans (52), 220 
although it should be noted that the affinity for ser68 residue is affected by the phosphorylation 221 
status of the adjacent thr69. Thus, the amount of ser68 phosphorylation, as determined by 222 
AB_FXYD1ser68 (Fig. 3C), can be underestimated if thr69 is phosphorylated (18). Similarly, 223 
9 
 
FXYD1 thr69 phosphorylation (Fig. 3E) can be affected by the phosphorylation status of the ser68 224 
residue. 225 
Furthermore, a new batch of FXYD1 phospho-specific antibodies: FXYD1ser63, FXYD1ser68 and 226 
FXYD1thr69 (developed by Will Fuller and Michael Shattock), have also been used. These 227 
antibodies were used in mouse and rat ventricular myocytes, where FXYD1 is poorly 228 
phosphorylated at thr69 (16), however, in vitro phosphorylation data indicates (18) that the 229 
FXYD1ser68 and FXYD1thr69 antibodies are affected to the similar extent as the older generation 230 
of antibodies, AB_FXYD1ser68 and AB_FXYD1. Indeed, in our study, FXYD1 ser68 231 
phosphorylation data obtained by the FXYD1ser68 and AB_FXYD1ser68 antibodies were similar 232 
and thus, for simplicity, only data obtained using AB_FXYD1ser68 are included in the results 233 
section. 234 
In order to take into account the phospho-specificity and -sensitivity of the used antibodies, 235 
AB_FXYD1ser68/AB_FXYD1 ratio (Fig 3D) was used as an alternative to determine ser68 236 
phosphorylation (Fig. 3C), as done in the past (54), whereas, FXYD1thr69/AB_FXYD1 (Fig. 3F) 237 
was used as alternative to determine thr69 phosphorylation (Fig. 3E). These ratios may overcome 238 
that the determination of FXYD1 ser68 and thr69 phosphorylation probably are affected by 239 
simultaneously phosphorylation at the two sites located next to each other. Data obtained from the 240 
ratio FXYD1ser68/AB_FXYD1 were similar to AB_FXYD1ser68/AB_FXYD1 and not included. 241 
 242 
Data treatment  243 
For each muscle sample, protein expression and phosphorylation was determined in duplicate 244 
(except for three muscle samples where only one measure was performed due to limited muscle 245 
tissue) and the average intensities were calculated. Values for all the individual time points were 246 
compared with the average resting value before the training intervention. 247 
Training induced changes in total protein expression and phosphorylation are shown in relation to 248 
the total expression of the same protein, where both are determined, e.g. mTOR 249 
phosphorylation/mTOR expression. Determination of the specific phosphorylation level and total 250 
protein expression was performed on separate membranes in separated analyses. 251 
 252 
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Statistics 253 
Changes in protein phosphorylation and expression were evaluated by a Two-way repeated measure 254 
ANOVA. If overall significant main effects were observed, a Student-Newman-Keul post-hoc 255 
analysis was conducted to identify differences in protein phosphorylation within specific time 256 
points (SigmaPlot 11.0). P < 0.05 was chosen as the level of significance.  257 
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Results 258 
Effect of the training intervention on protein expression 259 
Total expression of muscle FXYD1, CaMKII γ/δ, PLN, mTOR and actin was 30% (P<0.01), 25% 260 
(P<0.01), 16% (P<0.01), 12% (P<0.05) and 40% (P<0.05) higher after than before the training 261 
intervention. The expression of 4E-BP1 was 24% lower (P<0.05) after than before the training 262 
intervention. CaMKII βM expression tended (P=0.072) to be higher after compared to before the 263 
training intervention, whereas the expression of AMPKα2, eEF2 and p70S6K1 was not changed 264 
with the training intervention (Table 2).  265 
 266 
Effect of the training intervention on protein phosphorylation during intense exercise 267 
Non-specific FXYD1 phosphorylation was higher (P<0.05) at all time-points during the repeated 268 
intense exercise, compared to rest. After the training intervention period, non-specific FXYD1 269 
phosphorylation was higher (P<0.05) after EX1 and before EX2, than before the training 270 
intervention (Fig. 3A). 271 
FXYD1 ser63 phosphorylation was not altered during the repeated intense exercise, nor was it 272 
changed with the training intervention (Fig. 3B). 273 
FXYD1 ser68 phosphorylation was higher (P<0.001) at the end of EX1, compared to rest, 274 
decreased (P<0.001) after EX1, and then increased (P<0.05) after compared to before EX2 (Fig. 275 
3D). Furthermore, FXYD1 ser68 phosphorylation was higher (P<0.05) at rest and throughout the 276 
repeated intense exercise protocol after compared to before the training intervention (Fig. 3C and 277 
3D). 278 
FXYD1 thr69 phosphorylation was higher (P<0.05) after EX1, before and after EX2 compared to 279 
rest, while the training intervention did not affect FXYD1 thr69 phosphorylation (Fig. 3F). 280 
 281 
PKCα/β thr638/641 phosphorylation 282 
PKCα/β thr638/641 phosphorylation did not change during the repeated intense exercise, but after 283 
the training intervention, it was higher (P<0.01) before EX2 compared to rest (Table 3). After the 284 
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training intervention PKCα/β thr638/641 phosphorylation was higher at the end of EX1 (P<0.05) 285 
and before EX2 (P<0.01) compared to before the training intervention.  286 
 287 
CaMKII thr287, PLN thr17 and eEF2 thr56 phosphorylation  288 
Neither CaMKII βM nor γ/δ subunit thr287 phosphorylation was altered during the repeated high 289 
intensity exercise. After the training intervention CaMKII γ/δ thr287 phosphorylation was higher 290 
(P<0.01) at rest and both CaMKII βM and γ/δ thr287 phosphorylation were higher (P<0.01) before 291 
and after EX2, compared to before the training intervention (Table 3). 292 
After the training intervention Phospholamban (PLN) thr17 phosphorylation, was higher at rest 293 
(P<0.01) compared to before the intervention. Furthermore, before the training intervention, PLN 294 
thr17 phosphorylation was higher before EX2 compared to rest, while there were no changes in 295 
PLN thr17 phosphorylation with exercise after the training intervention (Table 3). 296 
Another CaMKII downstream target, eukaryotic elongation factor 2 (eEF2) thr56 phosphorylation, 297 
was increased at rest (P<0.01) and after EX2 (P<0.05) after the training intervention compared to 298 
before. Before the training intervention eEF2 thr56 phosphorylation after EX2 was higher (P<0.05) 299 
than at rest, while after the intervention the eEF2 thr56 phosphorylation after EX2 was higher 300 
(P<0.05) than at all other time points (Table 3). 301 
 302 
mTOR ser2448, p70S6K1 thr389 and 4E-BP1 thr37/46 phosphorylation 303 
Phosphorylation of mTOR ser2448 tended (P=0.064) overall to change during the exercise bouts. 304 
After the training intervention mTOR ser2448 phosphorylation was higher before EX2 (P<0.01) 305 
and after EX2 (P<0.05), compared to before the training intervention (Table 3). 306 
Before the training intervention mTORC1 activity determined by p70S6K1 thr389 phosphorylation 307 
at all time points was higher (P<0.05) compared to rest. After the training intervention p70S6K 308 
thr389 phosphorylation was higher (P<0.05) after EX1 compared to rest (Table 3). 309 
The mTOR substrate eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) thr37/46 310 
phosphorylation was not changed with neither exercise nor training (Table 3). 311 
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 312 
AMPKα thr172 and ACC β Ser221 phosphorylation 313 
Before the training intervention, AMPKα thr172 phosphorylation was higher (P<0.01) after EX2 314 
compared to the other time points. After the training intervention AMPKα thr172 phosphorylation 315 
after EX2 was lower (P<0.01) than before the training intervention (Table 3).  316 
As a downstream target of AMPK, the ACC β ser221 phosphorylation was higher after EX1 317 
(P<0.001) and before EX2 (P<0.01) compared to rest, and was further increased (P<0.05) at 318 
exhaustion, but was not affected by the training intervention (Table 3). 319 
 320 
  321 
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Discussion 322 
The main findings of the present experiment were that seven weeks of intensive training, with a 323 
reduced training volume, increased the total expression of FXYD1 and elevated the resting non-324 
specific FXYD1 phosphorylation level in endurance trained cyclist. In addition, repeated intense 325 
exercise after the training intervention induced a higher level of non-specific FXYD1 326 
phosphorylation than before the intervention. This was dominated by higher phosphorylation at 327 
FXYD1 ser68 residues. Other important findings were that the training intervention elevated the 328 
expression of actin, mTOR, PLN and CaMKII γ/δ and lowered the 4E-BP1 expression. 329 
Furthermore, the resting PLN thr17 phosphorylation, the overall PKCα/β thr638/641 and mTOR 330 
ser2448 phosphorylation during repeated intense exercise as well as CaMKII thr287, and eEF2 331 
thr56 phosphorylation at rest and during exercise was higher after compared to before the training 332 
intervention. 333 
Total FXYD1 expression was higher after compared to before the intensified training period, with 334 
no change in NaK pump α- and β-isoform expression (NaKα1: -11%, NaKα2: -8%, NaKβ1: -3%; 335 
(23). In contrast, no change in total FXYD1 expression, but elevated NaK pump α1-, α2- and β1-336 
isoform protein expressions were shown after 10 days of moderate intensity (75-100% of VO2 peak) 337 
cycle training in recreationally active subjects (5). Thus, it appears that the intensity of training 338 
and/or the training status of the subjects are important for adaptation of muscle FXYD1. In support 339 
of the first notion, sprint training in rats induced higher muscle FXYD1 levels, while endurance 340 
training did not have any effect on FXYD1 expression (38). Treadmill running with a 10%-grade, 5 341 
days a week for 45 min in about 14 weeks, elevated FXYD1 expression in rat skeletal muscles (40). 342 
The different effect of the various training forms may have been caused by the degree of the FT 343 
muscle fiber stimulation, as FT muscle fibers are expected to be more activated during the intense 344 
training. In agreement, it has been demonstrated in humans, that the exercise (5 min cycling at 95% 345 
of VO2 max) induced change in FXYD1 phosphorylation is more pronounced in type II fibers than in 346 
type I fibers (51). 347 
In the resting state, non-specific FXYD1 phosphorylation and ser68 phosphorylation was higher 348 
after compared to before the training intervention. In agreement, a higher level of FXYD1 ser68 349 
phosphorylation at rest was observed after two weeks of intensified training in soccer players (54). 350 
In contrast, 10 days of moderate intensity exercise training did not induce changes in the resting 351 
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FXYD1 phosphorylation level (5), indicating that exercise intensity is also important for the 352 
training adaptations of FXYD1 phosphorylation at rest.  353 
During the repeated intense exercise the non-specific FXYD1 phosphorylation increased due to 354 
greater ser68 and thr69 phosphorylation, which is also observed during exercise with moderate 355 
intensity (52). On the other hand, FXYD1 ser63 phosphorylation did not change during the short 356 
and intense repeated exercise protocol as shown after 20-30 min of moderate intensity exercise (5; 357 
52). This may be explained by the lack of increase in PKCα/β thr638/641 phosphorylation level, as 358 
ser63 phosphorylation is PKC mediated (7; 36). The duration of the repeated intense exercise 359 
protocol may have been too short or the intensity too high to induce ser63 phosphorylation. FXYD1 360 
thr69 phosphorylation increased after EX1 and stayed elevated during the repeated intense exercise 361 
protocol, while ser68 phosphorylation increased during both exercise bouts and decreased in 362 
recovery from EX1. These marked increases in FXYD1 phosphorylation levels during exercise 363 
suggest that FXYD1 phosphorylation may play a crucial role in regulation of the NaK pump, and 364 
hence, K+ regulation during and after intense exercise, where K+ fluxes are pronounced (24; 28). 365 
Thus, in the same study it was observed that the average venous K+ concentration during the first 2 366 
min of recovery from the intense exercise bouts was lower (P<0.05) after compared to before the 367 
training intervention (4.2±0.2 vs. 4.9±0.2 and 4.3±0.2 vs. 5.1±0.1 mM), suggesting an enhanced 368 
muscle K+ reuptake, without changes in the expression of NaK pumps subunits (20). Furthermore, 369 
performance during repeated intense exercise was improved with the training intervention (256 vs. 370 
217 s) (23). 371 
After the training intervention non-specific FXYD1 phosphorylation was higher at the end of EX1 372 
and before EX2, due to higher FXYD1 ser68 phosphorylation, compared to before the intervention. 373 
The training intervention did not affect FXYD1 thr69 phosphorylation, which is in agreement with 374 
findings after a period of moderate intensity training (5). The training induced increase in PKCα/β 375 
thr638/641 phosphorylation may have contributed to the elevated FXYD1 phosphorylation, since 376 
PKCα activity has been shown to be required for contraction induced FXYD1 phosphorylation in 377 
mouse skeletal muscles (52) and other tissues (7; 18; 35). 378 
The higher expression of FXYD1 and FXYD1 phosphorylation after compared to before the 379 
training intervention may have affected the NaK pump activity and, hence, muscle potassium 380 
reuptake at rest and during contractions (10). In rat skeletal muscles around 30% of the α-subunits 381 
were co-expressed with FXYD1 (39), and the finding of a larger amount of FXYD1 may suggest a 382 
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higher degree of NaK pumps found as α/β/FXYD1 or a higher pool of free FXYD1 proteins. It has 383 
been shown in Xenopus oocytes, that the affinity for potassium (K+) and especially sodium (Na+) is 384 
lower for α/β/FXYD1 pumps compared to α/β pumps (both α1/β1 and α2/β1) without differences in 385 
the maximal pump activity (13). Thus, at rest a potential higher amount of α/β/FXYD1 pumps after 386 
compared to before the training intervention may per se lower the NaK pump activity, but it may 387 
also have been counterbalanced by an increased Na+ affinity expected from a higher resting FXYD1 388 
phosphorylation (7; 35). 389 
Incubation of rat muscle tissue homogenates with an anti-FXYD1 antibody lowered the NaK 390 
enzymatic activity by more than 50% compared to samples with no treatment (40), indicating that 391 
more FXYD1 increases the activity of NaK pumps in muscles through a higher amount of NaK 392 
pumps found as α/β/FXYD1. In addition, a higher pool of free FXYD1 after compared to before the 393 
training intervention, may have elevated the NaK pump activity during contractions. Indeed, 394 
FXYD1 has been suggested to translocate from an intracellular pool to the sarcolemma membrane 395 
during contractions, concomitant with an increased association between FXYD1 and the α1-subunit 396 
and a higher pump activity in the sarcolemma membrane fraction (39). Furthermore, the higher 397 
FXYD1 phosphorylation after the training intervention may have improved the pump activity 398 
through both a higher Na+ affinity (27) and a higher Vmax (34; 35). Thus, during exercise both the 399 
higher FXYD1 expression and phosphorylation may have contributed to an increased NaK pump 400 
activity after the training intervention compared to before. Unfortunately, the maximal NaK pump 401 
activity could not be determined due to lack of muscle tissue. Nevertheless, a higher activity of the 402 
NaK pump during and after exercise may explain the observation of lowered femoral venous 403 
plasma K+ concentration in the first 2 min of recovery after EX1 and EX2 as a result of the training 404 
intervention (23). 405 
An increased exercise-induced extracellular K+ concentration has been linked to depolarization of 406 
the muscle membranes, decreased excitability and muscle fatigue. Therefore higher muscle K+ 407 
reuptake is expected to improve performance. Improved K+ handling and exercise performance has 408 
been related to higher NaK pump content after a period of training (25; 31-33). On the other hand, 409 
high intensity training has augmented maximal pump activity despite unchanged total pump content 410 
and protein isoform expression (3). FXYD1 expression and phosphorylation were not determined in 411 
either of these studies and adaptations in the FXYD1 proteins may be the missing link explaining 412 
increased NaK pump activity without changes in pump content or isoform expression (3). 413 
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Concomitant adaptations in the NaK pump α2-subunit and FXYD1 phosphorylation have 414 
previously been demonstrated after intensified training (54). Thus, the adaptations in FXYD1 415 
expression and FXYD1 phosphorylation shown here may have improved K+ handling during 416 
exercise, despite no changes in NaK pump subunit expression. It is interesting to hypothesize that 417 
these adaptations in the FXYD1 protein may be the cause of the improved performance during 418 
repeated high intensity exercise of already trained athletes after the intensified training intervention 419 
with reduced training volume, as observed in the present study (23). 420 
An improved performance as a result of the training intervention (23) may also have been related to 421 
an improved intracellular Ca2+ handling (20). The high intensity training intervention with reduced 422 
volume induced increases in the CaMKII γ/δ isoforms while the CaMKII βM tended to be higher. 423 
The elevated CaMKII expression was associated with a higher expression of PLN and a higher 424 
resting phosphorylation of the substrate phospholamban thr17, which relieves the phospholamban 425 
inhibition on SERCA, allowing a higher Ca2+ affinity and, thus, a higher rate of Ca2+ uptake (48). A 426 
higher content of PLN with the same degree of thr17 phosphorylation would most likely lead to 427 
better Ca2+ homeostasis in the trained muscle (47), as observed previously in rats (26). It should be 428 
noted, however, that the changes in CaMKII expression in the present study were less pronounced 429 
than with 10 days of endurance training (4) and three weeks of one-legged endurance exercise 430 
training, which doubled the CaMKII activity, CaMKII kinase isoform expression and CaMKII 431 
autophosphorylation in resting muscles (47). On the other hand, the changes in PLN expression and 432 
thr17 phosphorylation at rest as well as in CaMKII thr287 phosphorylation (up to 8-fold increases) 433 
at rest and throughout the repeated intense exercise protocol shown after the intense training 434 
intervention, were either not seen after 10 days of endurance training (4) or were less pronounced 435 
after three weeks of endurance training (47), even though the subjects in the present study were 436 
trained before the intervention period. Thus, adaptations in PLN expression and CaMKII thr287 437 
phosphorylation seem to be intensity dependent. CaMKII phosphorylation accelerates ATP 438 
provision via glycogenolysis and glycolysis during contractions (48) and may explain why higher 439 
muscle lactate levels were observed during exercise after the training intervention (23). 440 
AMPK thr172 phosphorylation at exhaustion was lower after the intervention period. In accordance, 441 
10 days of endurance exercise training abolished a 9-fold increase in AMPK α2 activity, observed 442 
during prolonged exercise before the training period (29). On the other hand, in the present 443 
experiment the downstream target of AMPK, ACCser221 phosphorylation was not affected by the 444 
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training intervention, which was observed after a period of endurance training (4; 29). These 445 
findings indicate that high intensity training has an impact on AMPK signaling, but the effect is less 446 
pronounced than seen after endurance training. When the energy sensing and signaling protein 447 
AMPK is activated, it increases ATP production by stimulation of glucose uptake and fatty acid 448 
oxidation. Furthermore activation of AMPK inhibits ATP consuming processes such as protein 449 
synthesis (56). The observed decrease in the exercise induced AMPK thr172 phosphorylation after 450 
the training intervention may indicate an abolished AMPK activity during high intensity exercise 451 
even though other factors are involved. A decrease in AMPK activity will improve the ability for 452 
ATP consuming processes in the muscle cell, such as an increased NaK pump activity, which may 453 
contribute to improved K+ handling and the improved performance. In support for a link between 454 
AMPK and NaK pump activity, repeated treatment of mice with the AMPK activator AICAR 455 
increased FXYD1 phosphorylation and affected the NaK pump activity by increasing the Na+ 456 
affinity (27). 457 
AMPK may be involved in the regulation of mTOR, as elevated AMPK signaling lowers mTOR 458 
signaling in mouse skeletal muscles (14), while it is presently unclear whether it also occurs in 459 
humans (19). Thus, the abolished AMPK phosphorylation after the training intervention may have 460 
caused the increased expression of mTOR as well as mTOR ser2448 phosphorylation. These 461 
increases in mTOR and ser2448 phosphorylation were similar to the adaptations seen after 462 
moderate intensity training (4) and appear not to be intensity dependent. The mTOR signaling 463 
pathway is involved in many processes in the muscle cell including pathways controlling protein 464 
synthesis and muscle hypertrophy (12; 22). The increased actin expression may indicate muscle 465 
hypertrophy. It is supported by a training induced decrease in 4E-BP1 expression, which may have 466 
reduced eIF4E/4E-BP1 binding and elevated translation initiation (22). The mTORC1 readout 467 
p70S6K1 thr389 phosphorylation was in the present study higher during 2 x 2-4 min of high 468 
intensity exercise, which is in contrast to shorter high intensity exercise bouts (11; 21). During the 469 
training intervention both 30-s and 4-min bouts were performed, thus mTORC1 may have been 470 
activated during the training and may have induced hypertrophy. On the other hand, both exercise 471 
and training induced an increase in the downstream target of CaMKII, eEF2 thr56 phosphorylation 472 
(19; 37)¸ which is expected to lower protein synthesis by lowering the eEF2 interaction with the 473 
ribosome and, thereby, impairing the elongation rate (37). Likewise, acute endurance exercise and 474 
endurance exercise training intervention, where hypertrophy is not expected, do lead to higher eEF2 475 
thr56 phosphorylation levels (55). The higher eEF2 thr56 phosphorylation observed at rest after the 476 
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training intervention is expected to blunt the overall muscle protein synthesis (49) and does not 477 
indicate hypertrophy. In support, mean or peak power output during the initial sprint was not 478 
changed with the training intervention (23). Thus, it is unclear whether the intervention did lead to 479 
mTORC1 induced muscle hypertrophy and further studies are warranted to examine whether high 480 
intensity exercise training can lead to hypertrophy in already endurance trained individuals. 481 
In summary, seven weeks of high intensity training with reduced training volume in endurance 482 
trained cyclist increased FXYD1 expression and FXYD1 phosphorylation levels and may have 483 
caused the improved K+ reuptake during the intense repeated exercise, thus possibly contributing to 484 
the improved performance. Furthermore, the intense training intervention induced adaptations in 485 
CaMKII and PLN expression as well as CaMKII phosphorylation that may improve intracellular 486 
Ca2+ handling during exercise, which may potentially contribute to the improved performance. 487 
 488 
Perspectives and Significance 489 
The present study showed that high intensity exercise training in combination with a reduced 490 
training volume can induce significant adaptations in already endurance trained cyclists. It also 491 
demonstrated that it is important to examine changes in muscle protein phosphorylation and 492 
signaling during acute exercise before and after a training intervention. Higher FXYD1 expression 493 
and phosphorylation as well as CaMKII signaling may have elevated K+ reuptake (23), via 494 
increased NaK pump activity (13; 27; 34; 35), and improved Ca2+ handling (26; 47; 48), 495 
respectively, but these effects need to be examined and possible links to improved excitation-496 
contraction coupling should be investigated. Further studies are also warranted to clarify the effects 497 
of high intensity exercise training with reduced training volume on muscle hypertrophy and the 498 
signaling mechanisms regulating protein synthesis. 499 
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Figure and table legends 679 
Figure 1 680 
A Schematic illustration of the protocol performed on the experimental day. Muscle biopsies were 681 
obtained at the time points indicated by solid arrows. A fifth biopsy was as well obtained at rest in 682 
the morning, indicated by the dashed arrow, but data from this biopsy is not included in the article. 683 
The present article only includes data related to the repeated intense exercise protocol performed at 684 
the end of the experimental day. iPPO, incremental peak power output.  685 
 686 
Figure 2 687 
Representative western blots, including the molecular weight of band migration. 4E-BP1: 688 
eukaryotic initiation factor 4E-binding protein 1; ACCβ Ser221 phos: Acetyl-CoA carboxylase β 689 
serine 221 phosphorylation; AMPKα2: AMP-activated Protein Kinase α2; CaMKII: 690 
Ca2+/Calmodulin-dependent Protein Kinase II; eEF2: Eukaryotic elongation factor 2; FXYD1: 691 
phospholemman; mTOR: mammalian target of rapamycin; PKCα/β Thr638/641 phos: protein 692 
kinase Cα/β threonine 638/641 phosphorylation; p70S6K1: Ribosomal protein S6 p70 Kinase 1; 693 
PLN: Phospholamban. 694 
 695 
Figure 3A 696 
Muscle protein non-specific FXYD1 phosphorylation at rest and during repeated intense exercise 697 
(EX1 and EX2) before (PRE) and after (POST) 7 weeks of high-intensity training in combination 698 
with a reduced training volume in trained cyclist (n=7). Data are normalized to mean at rest before 699 
the intervention period (PRE) and expressed as means ± SEM. The overall statistical effects – Acute 700 
exercise: P>0.001, Training: P=0.012 and Interaction: P=0.232. * Post higher than Pre. # Rest lower 701 
than all other time points. $ Rest lower than all other time points after IT (Post). ¤ End of EX1 and 702 
EX2 higher than rest before IT (Pre) and ¤¤ End of EX2 higher than before EX2 before IT (Pre). 703 
 704 
 705 
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Figure 3B 706 
Muscle protein FXYD1 ser63 phosphorylation at rest and during repeated intense exercise (EX1 707 
and EX2) before (PRE) and after (POST) 7 weeks of high-intensity training in combination with a 708 
reduced training volume in trained cyclist (n=7). Data are normalized to mean at rest before the 709 
intervention period (PRE) and expressed as means ± SEM. The overall statistical effects – Acute 710 
exercise: P=0.359, Training: P=0.938 and Interaction: P=0.165. 711 
 712 
Figure 3C  713 
Muscle protein FXYD1 ser68 phosphorylation at rest and during repeated intense exercise (EX1 714 
and EX2) before (PRE) and after (POST) 7 weeks of high-intensity training in combination with a 715 
reduced training volume in trained cyclist (n=7). Data are normalized to mean at rest before the 716 
intervention period (PRE) and expressed as means ± SEM. The overall statistical effects – Acute 717 
exercise: P=0.053, Training: P=0.046 and Interaction: P=0.520. * Post higher than Pre. 718 
 719 
Figure 3D  720 
Muscle protein FXYD1 ser68 phosphorylation, considering antibody phospho-sensitivity, at rest 721 
and during repeated intense exercise (EX1 and EX2) before (PRE) and after (POST) 7 weeks of 722 
high-intensity training in combination with a reduced training volume in trained cyclist (n=7). Data 723 
are normalized to mean at rest before the intervention period (PRE) and expressed as means ± SEM. 724 
The overall statistical effects – Acute exercise: P<0.001, Training: P=0.004 and Interaction: 725 
P=0.920. * Post higher than Pre. # End of EX1 higher than all other time points. ## End of EX2 726 
higher than Rest and before EX2. $ End of EX1 higher than all other time points after IT (Post). ¤ 727 
End of EX1 higher than Rest and before EX2 before IT (Pre). 728 
 729 
Figure 3E  730 
Muscle protein FXYD1 thr69 phosphorylation at rest and during repeated intense exercise (EX1 731 
and EX2) before (PRE) and after (POST) 7 weeks of high-intensity training in combination with a 732 
32 
 
reduced training volume in trained cyclist (n=7). Data are normalized to mean at rest before the 733 
intervention period (PRE) and expressed as means ± SEM. The overall statistical effects – Acute 734 
exercise: P=0.824, Training: P=0.001 and Interaction: P=0.937. * Post lower than Pre. 735 
 736 
Figure 3F  737 
Muscle protein FXYD1 thr69 phosphorylation, considering antibody phospho-sensitivity, at rest 738 
and during repeated intense exercise (EX1 and EX2) before (PRE) and after (POST) 7 weeks of 739 
high-intensity training in combination with a reduced training volume in trained cyclist (n=7). Data 740 
are normalized to mean at rest before the intervention period (PRE) and expressed as means ± SEM. 741 
The overall statistical effects – Acute exercise: P=0.006, Training: P=0.071 and Interaction: 742 
P=0.723. # Rest lower than all other time points. ¤ End of EX1 and End of EX2 higher than Rest 743 
before IT (Pre). 744 
 745 
Table 1 746 
Antibody overview 747 
4E-BP1: eukaryotic initiation factor 4E-binding protein 1; ACCβ Ser221 phos: Acetyl-CoA 748 
carboxylase β serine 221 phosphorylation; AMPKα2: AMP-activated Protein Kinase α2; CaMKII: 749 
Ca2+/Calmodulin-dependent Protein Kinase II; eEF2: Eukaryotic elongation factor 2; FXYD1: 750 
phospholemman; mTOR: mammalian target of rapamycin; PKCα/β Thr638/641 phos: protein 751 
kinase Cα/β threonine 638/641 phosphorylation; p70S6K1: Ribosomal protein S6 p70 Kinase 1; 752 
PLN: Phospholamban. 753 
 754 
Table 2 755 
Muscle protein expression at rest, before and after 7 weeks of high-intensity training in 756 
combination with a reduced training volume in trained cyclist 757 
4E-BP1: eukaryotic initiation factor 4E-binding protein 1; AMPKα2: AMP-activated Protein 758 
Kinase α2; CaMKII: Ca2+/Calmodulin-dependent Protein Kinase II; eEF2: Eukaryotic elongation 759 
33 
 
factor 2; FXYD1: phospholemman; mTOR: mammalian target of rapamycin; p70S6K1: Ribosomal 760 
protein S6 p70 Kinase 1; PLN: Phospholamban. Values are means ± SE in arbitrary units; n = 7. 761 
The main statistical P-values obtained from a Two-way RM ANOVA statistical analysis are 762 
expressed. Protein expression is different after compared to before the training intervention * P < 763 
0.05, and ** P < 0.01. Protein expression tended to be different after compared to before the 764 
training intervention # P < 0.10. 765 
 766 
Table 3 767 
Changes in protein phosphorylation at rest and during the repeated intense exercise protocol 768 
before and after 7 weeks of high-intensity training with a reduced training volume in trained 769 
cyclist 770 
4E-BP1: eukaryotic initiation factor 4E-binding protein 1; ACCβ: Acetyl-CoA carboxylase β; 771 
AMPKα2: AMP-activated Protein Kinase α2; CaMKII: Ca2+/Calmodulin-dependent Protein Kinase 772 
II; eEF2: Eukaryotic elongation factor 2; mTOR: mammalian target of rapamycin; PKCα/β: protein 773 
kinase C α/β; p70S6K1: Ribosomal protein S6 p70 Kinase 1; PLN: Phospholamban. E: Acute 774 
exercise, T: Training, I: Interaction, End of EX1: After the first intense exercise bout lasting 2min, 775 
Before EX2: Before the second exercise bout and End of EX2: after the second high intensity 776 
exercise bout performed to exhaustion. Data are expressed as means±SE. * PRE higher than POST. 777 
** POST higher than PRE. $ Higher than Rest within PRE or POST, $$ Higher than all other time 778 
points within PRE or POST, # Higher than Rest, ## Higher than all other time points, ¤ Higher than 779 
before EX2.  780 
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Table 1 Antibody overview 781 
Protein target Ab cat. number or name Company or donor Ab source Migration MW 
4E-BP1 #9452 Cell Signaling Technology rabbit 15-20 kDa 
4E-BP1 Thr37/46 phos #2855 Cell Signaling Technology rabbit 15-20 kDa 
ACCβ Ser221 phos #07-303 Millipore rabbit 259 kDa 
Actin A2066 Sigma Aldrich rabbit  42 kDa 
AMPKα2 AMPK α2 Dr. J. Birk, University of Copenhagen sheep 63 kDa 
AMPKα Thr172 phos #2531 Cell Signaling Technology rabbit 63 kDa 
CaMKII 611293 BD Transduction Laboratories mouse 55-75 kDa 
CaMKII Thr286 phos #3361 Cell Signaling Technology rabbit 55-75 kDa 
eEF2 ab130187 Abcam mouse 95 kDa 
eEF2 Thr56 phos #2331 Cell Signaling Technology rabbit 95 kDa 
FXYD1 13721-1-AP Proteintech rabbit 12 kDa 
FXYD1 unphosphorylated AB_FXYD1 – C2 Dr. J. Randall Moorman, University of Virginia rabbit 12 kDa 
FXYD1 Ser68 phos AB_FXYD1ser68 – CP68 Dr. D. Bers, Loyola University rabbit 12 kDa 
FXYD1 Ser63 phos FXYD1ser63 phos Professor M. Shattock, King’s College London rabbit 12 kDa 
FXYD1 Ser68 phos FXYD1ser68 phos Professor M. Shattock, King’s College London rabbit 12 kDa 
FXYD1 Thr69 phos FXYD1thr69 phos Professor M. Shattock, King’s College London sheep 12 kDa 
mTOR #2972 Cell Signaling Technology rabbit 289 kDa 
mTOR Ser2448 phos #2971 Cell Signaling Technology rabbit 289 kDa 
p70S6K1 #2708 Cell Signaling Technology rabbit 70 kDa 
p70S6K1 Thr389 phos #9234 Cell Signaling Technology rabbit 70 kDa 
PKCα/β Thr638/641 phos #9375 Cell Signaling Technology rabbit 80-82 kDa 
PLN PA5-19351 Pierce – ThermoScientific goat 6 kDa 
PLN Thr17 phos Sc-17024 Santa Cruz Biotechnology rabbit 6 kDa 
4E-BP1: eukaryotic initiation factor 4E-binding protein 1; ACCβ Ser221 phos: Acetyl-CoA carboxylase β serine 221 phosphorylation; AMPKα2: AMP-782 
activated Protein Kinase α2; CaMKII: Ca2+/Calmodulin-dependent Protein Kinase II; eEF2: Eukaryotic elongation factor 2; FXYD1: phospholemman; 783 
mTOR: mammalian target of rapamycin; PKCα/β Thr638/641 phos: protein kinase Cα/β threonine 638/641 phosphorylation; p70S6K1: Ribosomal 784 
protein S6 p70 Kinase 1; PLN: Phospholamban. 785 
 786 
  787 
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Table 2 Muscle protein expression before and after 7 weeks of high-intensity training in combination with a reduced 788 
training volume in trained cyclist.  789 
  Main statistical P-values for a Two-way RM ANOVA 
Protein / Antibody Before After Training Acute exercise Interaction 
4E-BP1 0.99 ± 0.06   0.75 ± 0.05* 0.013 0.896 0.850 
Actin 0.86 ± 0.05   1.26 ± 0.09* 0.018 0.399 0.828 
AMPKα2 1.00 ± 0.03 1.04 ± 0.04 0.325 0.285 0.965 
CaMKII βM 0.96 ± 0.07  1.19 ± 0.13# 0.072 0.563 0.771 
CaMKII γ/δ 0.92 ± 0.07    1.17 ± 0.11** 0.006 0.382 0.179 
eEF2 0.74 ± 0.05 0.80 ± 0.06 0.357 0.143 0.051 
FXYD1 0.98 ± 0.05    1.28 ± 0.08** 0.005 0.215 0.081 
mTOR 0.95 ± 0.05   1.07 ± 0.06* 0.015 0.630 0.211 
p70S6K1 0.87 ± 0.03 0.88 ± 0.04 0.570 0.106 0.030 
PLN 1.06 ± 0.05    1.22 ± 0.06** 0.007 0.470 0.328 
4E-BP1: eukaryotic initiation factor 4E-binding protein 1; AMPKα2: AMP-activated Protein Kinase α2; CaMKII: 790 
Ca2+/Calmodulin-dependent Protein Kinase II; eEF2: Eukaryotic elongation factor 2; FXYD1: phospholemman; 791 
mTOR: mammalian target of rapamycin; p70S6K1: Ribosomal protein S6 p70 Kinase 1; PLN: Phospholamban. 792 
Values are means ± SE in arbitrary units; n = 7. The main statistical P-values obtained from a Two-way RM ANOVA 793 
statistical analysis are expressed. Protein expression is different after compared to before the training intervention * P 794 
< 0.05, and ** P < 0.01. Protein expression tended to be different after compared to before the training intervention # 795 
P < 0.10. 796 
  797 
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Table 3. Changes in protein phosphorylation at rest and during the repeated intense exercise protocol before and after 7 weeks of 798 
high-intensity training in combination with a reduced training volume in trained cyclist 799 
Target Main effects ANOVA P-values Time Rest End of EX1 Before EX2 End of EX2 
       
PKCα/β thr638/641 
E: P=0.240 
T: P=0.036 
I: P=0.029
PRE 
POST 
1.00±0.12 
0.81±0.09 
0.75±0.09 
   1.03±0.20** 
0.88±0.09 
     1.27±0.16**$ 
0.93±0.07 
1.05±0.16 
       
CaMKIIβ thr287 
E: P=0.156 
T: P=0.014 
I: P=0.337 
PRE 
POST 
1.00±0.24 
6.03±1.04 
4.37±2.12 
8.95±2.34 
1.08±0.15 
    8.61±2.23** 
2.45±0.68 
  11.32±3.77** 
       
CaMKIIγ/δ thr287 
E: P=0.279 
T: P=0.004 
I: P=0.263 
PRE 
POST 
1.00±0.27 
    5.48±1.21** 
3.81±1.38 
6.10±1.37 
1.06±0.13 
    6.22±1.52** 
1.96±0.35 
   7.30±2.09** 
       
       
PLN thr17 
E: P=0.117 
T: P=0.235 
I: P=0.039 
PRE 
POST 
1.00±0.16 
   1.42±0.07** 
1.37±0.05 
1.31±0.07 
  1.52±0.12$ 
1.44±0.14 
1.14±0.10 
1.21±0.09 
       
       
eEF2 thr56 
E: P=0.007 
T: P=0.002 
I: P=0.086
PRE 
POST 
1.00±0.19 
   3.16±0.64** 
2.90±0.37 
2.87±0.47 
2.75±0.32 
2.60±0.51 
3.52±0.24##$ 
   5.29±0.99**##$$
       
mTOR ser2448 
E: P=0.064 
T: P=0.018 
I: P=0.139 
PRE 
POST 
1.00±0.13 
1.32±0.22 
1.63±0.25 
1.59±0.19 
0.99±0.13 
   1.62±0.30** 
1.28±0.15 
   1.72±0.14** 
       
p70S6K1 thr389 E: P=0.021 T: P=0.524 
PRE 
POST 
1.00±0.12 
1.47±0.29 
2.36±0.39#$ 
2.60±0.36#$ 
 1.96±0.34$ 
2.09±0.46 
 2.27±0.26$ 
1.95±0.23 
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I: P=0.178 
       
       
4E-BP1 thr37/46 
E: P=0.271 
T: P=0.197 
I: P=0.296 
PRE 
POST 
1.00±0.16 
1.01±0.25 
0.67±0.11 
0.73±0.11 
0.82±0.09 
0.93±0.17 
0.59±0.10 
0.88±0.18 
       
AMPKα thr172 
E: P=0.003 
T: P=0.210 
I: P=0.047 
PRE 
POST 
1.00±0.09 
0.90±0.10 
0.74±0.08 
0.65±0.14 
0.74±0.09 
0.79±0.11 
1.46±0.19*$$## 
1.03±0.10## 
       
ACCβ ser221 
E: P<0.001 
T: P=0.182 
I: P=0.558 
PRE 
POST 
   1.00±0.18 
  1.00±0.15 
 3.25±0.76#$ 
 2.51±0.37#$ 
 2.98±0.84#$ 
1.84±0.37# 
    3.99±0.86#$¤ 
    3.00±0.60#$¤ 
       
4E-BP1: eukaryotic initiation factor 4E-binding protein 1; ACCβ: Acetyl-CoA carboxylase β; AMPKα2: AMP-activated Protein Kinase α2; CaMKII: 800 
Ca2+/Calmodulin-dependent Protein Kinase II; eEF2: Eukaryotic elongation factor 2; mTOR: mammalian target of rapamycin; PKCα/β: protein kinase 801 
C α/β; p70S6K1: Ribosomal protein S6 p70 Kinase 1; PLN: Phospholamban. E: Acute exercise, T: Training, I: Interaction, End of EX1: After the first 802 
intense exercise bout lasting 2min, Before EX2: Before the second exercise bout and End of EX2: after the second high intensity exercise bout 803 
performed to exhaustion. Data are expressed as means±SE. * PRE higher than POST. ** POST higher than PRE. $ Higher than Rest within PRE or 804 
POST, $$ Higher than all other time points within PRE or POST, # Higher than Rest, ## Higher than all other time points, ¤ Higher than before EX2. 805 
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